RESMED INC (RMD) Financial Statements

Income statement

Metric	TTM	2026	2025	2024	2023
Revenue
Total Revenue	5.7B	5.7B	5.1B	4.7B	4.2B
Cost of Revenue	2.2B	2.2B	2.1B	2.0B	1.9B
Gross Profit	3.5B	3.5B	3.1B	2.7B	2.4B
Operating Expenses
R&D Expense	393.8M	378.3M	331.3M	307.5M	287.6M
SG&A Expense	1.2B	1.1B	991.0M	917.1M	874.0M
General & Admin Expense	314.7M	—	—	—	—
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	45.3M	45.5M	47.3M	110.7M	62.1M
Total Operating Expenses	1.6B	1.5B	1.4B	1.3B	1.2B
Cost and Expenses	3.8B	3.7B	3.5B	3.4B	3.1B
Operating Income (EBIT)	1.9B	1.9B	1.7B	1.3B	1.1B
Non-Operating
Interest Income	21.2M	—	—	—	—
Interest Expense	25.1M	—	12.6M	45.7M	47.4M
Net Interest Income	(3.9M)	—	(12.6M)	(45.7M)	(47.4M)
Other Non-Op Income/Expense	112.7M	11.0M	(7.8M)	(55.1M)	(30.2M)
Non-Operating Income (excl Interest)	(112.3M)	—	9.8M	9.4M	(30.4M)
EBT (Pre-Tax Income)	2.0B	1.9B	1.7B	1.3B	1.1B
Income Tax Expense	418.6M	396.1M	276.8M	243.8M	204.1M
Bottom Line
Net Income	1.6B	1.5B	1.4B	1.0B	897.6M
Earnings from Cont. Ops	1.6B	1.5B	1.4B	1.0B	897.6M
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	1.6B	1.5B	1.4B	1.0B	897.6M
Per Share
Basic EPS	$10.99	$10.44	$9.55	$6.94	$6.12
Diluted EPS	$10.95	$10.40	$9.51	$6.92	$6.09
Revenue Per Share	$40.09	$39.07	$35.08	$31.87	$28.77
Shares
Basic Shares Outstanding	143.0M	144.7M	146.7M	147.0M	146.8M
Diluted Shares Outstanding	143.4M	145.0M	147.3M	147.6M	147.5M
Profitability Metrics
EBITDA	2.2B	2.2B	1.9B	1.5B	1.4B
D&A	228.2M	244.2M	235.8M	216.2M	197.6M
EBIT	2.0B	1.9B	1.7B	1.3B	1.2B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026